Brief: Anebulo Pharmaceuticals Announces Positive Interim Data For Aneb-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication
26/09/2022 12:04
Sept 26 (Reuters) - Anebulo Pharmaceuticals Inc
ANEB.O :
* ANEBULO PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM DATA
FOR
ANEB-001 FROM PART B OF ITS PHASE 2 CLINICAL TRIAL FOR ACUTE
CANNABINOID INTOXICATION
* ANEBULO PHARMACEUTICALS INC - LOWER DOSES OF ANEB-001
REDUCED
NEGATIVE EFFECTS OF HIGHER DOSES OF THC
* ANEBULO PHARMACEUTICALS INC - CURRENTLY EXPLORING DELAYED
DOSING
TOBETTER UNDERSTAND REAL-WORLD CONDITIONS
Source text for Eikon: ID:nBw8MP8s2a
Further company coverage: ANEB.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Anebulo Pharmaceuticals
See all newsAdvisory: Dated alert on Anebulo Pharmaceuticals' voluntary delisting from Nasdaq withdrawn
Anebulo Pharmaceuticals Q2 net loss narrows
Brief: Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Anebulo Pharmaceuticals posts Q1 net loss
Brief: Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results